Big pharma stung in HHS fraud report

Half of the $4 billion in fraudulent health care claims recouped by the government last year came from big pharma. An HHS report cites fraud by drug and device makers, with Allergan's $600 million fine and settlement for off-label Botox marketing topping the list. Allergan is followed by Novartis Pharmaceuticals, with $422.5 million in fines; AstraZeneca, $520 million; Forest Laboratories and Forest Pharmaceuticals, $313 million; and Teva, $100 million. HHS release | Report (PDF)

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)